Tech Company Financing Transactions
Tangen Bioscience Funding Round
Tangen Bioscience, based in Branford, raised $9 million from Connecticut Innovations, Axiom Venture Partners and Leading Edge Ventures.
Transaction Overview
Company Name
Announced On
6/21/2019
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Series A
Investors
Connecticut Innovations (Lead Investor) (Daniel Wagner)
Proceeds Purpose
The financing proceeds will be used to accelerate the company's innovative platform TangenDx to the clinic for two infectious disease tests.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
780 East Main St. 1
Branford, CT 06405
USA
Branford, CT 06405
USA
Phone
Website
Email Address
Not Recorded
Overview
Tangen Bioscience's instrument provides rapid nucleic acid detection, with the specificity and sensitivity of polymerase chain reaction (PCR) amplification, in a format that does not require laboratory resources or highly skilled operators.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rick Birkmeyer
Chief Scientific Officer
John Davidson
VP - Engineering
Bernard Puc
VP - Finance
Anne Cavanaugh
VP - Operations
Brian Chirico
VP - Regulatory Affairs
Keith Kardos
VP - Regulatory Affairs
Robert McNamee
Browse more venture capital transactions:
Prev: 6/21/2019: Cypress.io venture capital transaction
Next: 6/21/2019: Druva venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are derived from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs